Performance
5 Days
0 0%
1 Month
0 0%
3 Months
0 0%
6 Months
0 0%
1 Year
0 0%
2 Year
0 0%
Key data
Stock price
$2.20
DAY RANGE
$2.20 - $2.20
52 WEEK RANGE
$0.56 - $8.60
52 WEEK CHANGE
-$67.07
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Larry Edwards
Region: US
Website: http://www.tphase.com
Employees: 67
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry:
Sector:
Region: US
Website: http://www.tphase.com
Employees: 67
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry:
Sector:
Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also engages in the development of product candidate, eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.
Recent news